Contact
Please use this form to send email to PR contact of this press release:
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory
TO: